EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Insmed's enterprise value is $4,282.8 Mil.
Insmed's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $305.2 Mil. Therefore, Insmed's EV-to-Revenue for today is 14.03.
The historical rank and industry rank for Insmed's EV-to-Revenue or its related term are showing as below:
INSM'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.72 Med: 34.35 Max: 224.55
Current: 14.03
During the past 13 years, the highest EV-to-Revenue of Insmed was 224.55. The lowest was 8.72. And the median was 34.35.
INSM's EV-to-Revenue is ranked worse than 62.27% of 1039
companies
in the Biotechnology industry
Industry Median: 8.37
vs INSM: 14.03
As of today (2024-05-12), Insmed's stock price is $25.97.
Insmed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.17. Therefore, Insmed's PS Ratio for today is 11.97.
Insmed EV-to-Revenue Historical Data
The historical data trend for Insmed's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Insmed's EV-to-Revenue falls into.
Insmed's current Enterprise Value is $4,282.8 Mil.
Insmed's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $305.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed's share price for today is $25.97.
Insmed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Insmed's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 